-
公开(公告)号:WO2007082742A1
公开(公告)日:2007-07-26
申请号:PCT/EP2007/000408
申请日:2007-01-18
申请人: MERCK PATENT GMBH , GOODMAN, Simon , GRELL, Matthias , TEN HAGEN, Timo, L., M. , EGERMONT, Alexander, M., M.
CPC分类号: A61K38/12 , A61K41/00 , A61K45/06 , A61K2300/00
摘要: The invention relates to a combination therapy for the treatment of tumors and tumor metastases comprising administration of integrin ligands, preferably integrin antagonists, together with co-therapeutic agents or therapy forms that have synergistic efficacy when administered together with said ligands, such as chemotherapeutic agents and/or radiation therapy, in isolated organ perfusion. The therapy results in a synergistic potential increase of the inhibition effect of each individual therapeutic on tumor cell proliferation, yielding more effective treatment than found by administering an individual component alone.
摘要翻译: 本发明涉及用于治疗肿瘤和肿瘤转移的组合疗法,其包括将整联蛋白配体,优选整联蛋白拮抗剂,以及当与所述配体如化学治疗剂一起施用时具有协同疗效的共同治疗剂或治疗形式, /或放射治疗,分离器官灌注。 治疗导致每个单独治疗剂对肿瘤细胞增殖的抑制作用的协同增加潜力,产生比通过单独施用单独组分发现的更有效的治疗。
-
公开(公告)号:WO2005082858A3
公开(公告)日:2005-11-10
申请号:PCT/EP2005000983
申请日:2005-02-01
申请人: MERCK PATENT GMBH , BUCHSTALLER HANS-PETER , BURGDORF LARS , FINSINGER DIRK , AMENDT CHRISTIANE , GRELL MATTHIAS , SIRRENBERG CHRISTIAN , ZENKE FRANK
发明人: BUCHSTALLER HANS-PETER , BURGDORF LARS , FINSINGER DIRK , AMENDT CHRISTIANE , GRELL MATTHIAS , SIRRENBERG CHRISTIAN , ZENKE FRANK
IPC分类号: A61K31/33 , A61K31/47 , C07C211/45 , C07C211/52 , C07C265/12 , C07D217/26 , C07D401/12 , C07D409/12 , C07D413/12 , C07D417/12 , A61P9/00 , A61P19/00 , A61P31/16 , A61P35/00
CPC分类号: C07D217/26 , C07C211/45 , C07C211/52 , C07C265/12 , C07D401/12 , C07D409/12 , C07D413/12 , C07D417/12
摘要: The present invention relates to isoquinoline derivatives of formula (I), the use of the compounds of formula (I), as inhibitors of one or more kinases, the use of the compounds of formula (I), for the manufacture of a pharmaceutical composition and a method of treatment, comprising administering said pharmaceutical composition to a patient.
摘要翻译: 本发明涉及式(I)的异喹啉衍生物,式(I)化合物作为一种或多种激酶的抑制剂的用途,式(I)化合物在制备药物组合物 和治疗方法,包括将所述药物组合物给予患者。
-
公开(公告)号:WO2005085202A1
公开(公告)日:2005-09-15
申请号:PCT/EP2005/000273
申请日:2005-01-13
申请人: MERCK PATENT GMBH , BURGDORF, Lars, Thore , BUCHSTALLER, Hans-Peter , STIEBER, Frank , AMENDT, Christiane , GREINER, Hartmut , GRELL, Matthias , SIRRENBERG, Christian , ZENKE, Frank
发明人: BURGDORF, Lars, Thore , BUCHSTALLER, Hans-Peter , STIEBER, Frank , AMENDT, Christiane , GREINER, Hartmut , GRELL, Matthias , SIRRENBERG, Christian , ZENKE, Frank
IPC分类号: C07D213/81
CPC分类号: C07D213/81 , C07D401/12
摘要: Die Erfindung betrifft substituierte Arylamid-Derivate der Formel (I), deren Herstellung und Verwendung zur Herstellung eines Medikaments zur Behandlung von Krankheiten, insbesondere Tumoren und/oder Krankheiten, die durch Angiogenese verursacht, vermittelt und/oder propagiert werden. Verbindungen der Formel (I) sind wirksame Inhibitoren der Tyrosinkinasen, insbesondere TIE-2 und VEGFR, und der Raf-Kinasen.
摘要翻译: 本发明涉及式(I)的取代的芳基酰胺衍生物,它们的制备和使用用于制备所述药物用于的疾病,尤其是肿瘤和/或预防由血管生成的疾病,介导和/或传播的治疗。 式(I)的化合物是酪氨酸激酶的有效抑制剂,特别是VEGFR和TIE-2,和Raf激酶。
-
公开(公告)号:WO2005004864A1
公开(公告)日:2005-01-20
申请号:PCT/EP2004/006419
申请日:2004-06-15
申请人: MERCK PATENT GMBH , BUCHSTALLER, Hans-Peter , FINSINGER, Dirk , WIESNER, Matthias , BURGDORF, Lars , AMENDT, Christiane , GRELL, Matthias , SIRRENBERG, Christian , ZENKE, Frank
发明人: BUCHSTALLER, Hans-Peter , FINSINGER, Dirk , WIESNER, Matthias , BURGDORF, Lars , AMENDT, Christiane , GRELL, Matthias , SIRRENBERG, Christian , ZENKE, Frank
IPC分类号: A61K31/4184
CPC分类号: C07D401/12
摘要: The present invention relates to benzimidazole derivatives of formula I, the use of the compounds of formula I as inhibitors of one or more kinases, the use of the compounds of formula I for the manufacture of a pharmaceutical composition and a method of treatment, comprising administering said pharmaceutical composition to a patient. Accordingly, the compound of Formula I or a pharmaceutically acceptable salt thereof is administered for the treatment of diseases mediated by one or more kinase pathways, preferably by the raf kinase pathway, especially cancers, [FORMULA]
摘要翻译: 本发明涉及式I的苯并咪唑衍生物,式I化合物作为一种或多种激酶抑制剂的用途,式I化合物用于制备药物组合物和治疗方法的用途,其包括给药 所述药物组合物对患者而言。 因此,式I化合物或其药学上可接受的盐被用于治疗由一种或多种激酶途径介导的疾病,优选地通过raf激酶途径,特别是癌症。[公式]
-
公开(公告)号:WO2003020320A3
公开(公告)日:2003-03-13
申请号:PCT/EP2002/009185
申请日:2002-08-16
申请人: FRAUNHOFER-GESELLSCHAFT ZUR FÖRDERUNG DER ANGEWANDTEN FORSCHUNG E. V. , TOVAR, Günter , SCHIESTEL, Thomas , BRUNNER, Herwig , PFIZENMAIER, Klaus , GRELL, Matthias , SCHEURICH, Peter , HAMMER, Angela
发明人: TOVAR, Günter , SCHIESTEL, Thomas , BRUNNER, Herwig , PFIZENMAIER, Klaus , GRELL, Matthias , SCHEURICH, Peter , HAMMER, Angela
IPC分类号: C07K17/00
摘要: Die vorliegende Erfindung betrifft Nanopartikel mit daran immobilisiertem Tumor-Nekrose-Faktor (TNF) oder Cytokin, wobei TNF oder das Cytokin vorzugs- weise in Form eines Trimers gerichtet und unter Beibehaltung seiner biologischen Aktivität am Träger immobilisiert ist, Verfahren zur gerichteten Immobilisierung von TNF oder Cytokin an Nanopartikeln, die Verwendung der immobilisierten TNF oder Cytokin aufweisenden Nanopartikel zur Identifizierung und/oder Isolierung von Cytokinoder TNF- Bindungspartnern sowie zur Identifizierung und/oder Isolierung von Hemmstoffen der Interaktion zwischen TNF oder Cytokin und seinen Bindungspartnern, die Verwendung derartiger Nanopartikel zur Herstellung einer pharmazeutischen Zusammensetzung, insbesondere zur Therapie von Tumoren, sowie pharmazeutische und diagnostische Zusammensetzungen, die derartige Nanopartikel enthalten.
-
公开(公告)号:WO2007082742A8
公开(公告)日:2008-05-15
申请号:PCT/EP2007000408
申请日:2007-01-18
申请人: MERCK PATENT GMBH , GOODMAN SIMON , GRELL MATTHIAS , TEN HAGEN TIMO L M , EGGERMONT ALEXANDER M M
CPC分类号: A61K38/12 , A61K41/00 , A61K45/06 , A61K2300/00
摘要: The invention relates to a combination therapy for the treatment of tumors and tumor metastases comprising administration of integrin ligands, preferably integrin antagonists, together with co-therapeutic agents or therapy forms that have synergistic efficacy when administered together with said ligands, such as chemotherapeutic agents and/or radiation therapy, in isolated organ perfusion. The therapy results in a synergistic potential increase of the inhibition effect of each individual therapeutic on tumor cell proliferation, yielding more effective treatment than found by administering an individual component alone.
摘要翻译: 本发明涉及用于治疗肿瘤和肿瘤转移的组合疗法,其包括将整联蛋白配体,优选整联蛋白拮抗剂,以及当与所述配体如化学治疗剂一起施用时具有协同效力的共同治疗剂或治疗形式, /或放射治疗,分离器官灌注。 治疗导致每个单独治疗剂对肿瘤细胞增殖的抑制作用的协同增加潜力,产生比通过单独施用单独组分发现的更有效的治疗。
-
公开(公告)号:WO2005085220A1
公开(公告)日:2005-09-15
申请号:PCT/EP2005/000908
申请日:2005-01-31
申请人: MERCK PATENT GMBH , BURGDORF, Lars , BUCHSTALLER, Hans-Peter , STIEBER, Frank , ANZALI, Soheila , AMENDT, Christiane , GREINER, Hartmut , GRELL, Matthias , SIRRENBERG, Christian , ZENKE, Frank
发明人: BURGDORF, Lars , BUCHSTALLER, Hans-Peter , STIEBER, Frank , ANZALI, Soheila , AMENDT, Christiane , GREINER, Hartmut , GRELL, Matthias , SIRRENBERG, Christian , ZENKE, Frank
IPC分类号: C07D285/135
CPC分类号: C07D285/135 , C07D417/06 , C07D417/12
摘要: Verwendung von Verbindungen der Formel (I) worin Ar t , Ar 2 und Z die in Patentanspruch 1 angegebenen Bedeutungen haben, zur Prophylaxe und/oder Behandlung von Krankheiten bei denen die Hemmung, Regulierung und/oder Modulation der Signaltransduktion von Kinasen, insbesondere der RAF-Kinasen, eine Rolle spielt.
摘要翻译: 式(I)的化合物的用途,其中Ar
中,Ar <2>和Z具有权利要求1中给出的含义,为疾病的预防和/或治疗,其中抑制,调节和/或调制激酶信号转导的 特别是RAF激酶,起到了重要作用。 -
公开(公告)号:WO2005082858A2
公开(公告)日:2005-09-09
申请号:PCT/EP2005/000983
申请日:2005-02-01
申请人: MERCK PATENT GMBH , BUCHSTALLER, Hans-Peter , BURGDORF, Lars , FINSINGER, Dirk , AMENDT, Christiane , GRELL, Matthias , SIRRENBERG, Christian , ZENKE, Frank
发明人: BUCHSTALLER, Hans-Peter , BURGDORF, Lars , FINSINGER, Dirk , AMENDT, Christiane , GRELL, Matthias , SIRRENBERG, Christian , ZENKE, Frank
IPC分类号: C07D217/26
CPC分类号: C07D217/26 , C07C211/45 , C07C211/52 , C07C265/12 , C07D401/12 , C07D409/12 , C07D413/12 , C07D417/12
摘要: The present invention relates to isoquinoline derivatives of formula (I), the use of the compounds of formula (I), as inhibitors of one or more kinases, the use of the compounds of formula (I), for the manufacture of a pharmaceutical composition and a method of treatment, comprising administering said pharmaceutical composition to a patient.
摘要翻译: 本发明涉及式(I)的异喹啉衍生物,式(I)化合物的用途,作为一种或多种激酶的抑制剂,使用式(I)化合物,用于制备药物组合物 和一种治疗方法,包括将药物组合物给予患者。
-
公开(公告)号:WO2005058832A1
公开(公告)日:2005-06-30
申请号:PCT/EP2004/012764
申请日:2004-11-11
申请人: MERCK PATENT GMBH , FINSINGER, Dirk , BUCHSTALLER, Hans-Peter , BURGDORF, Lars , AMENDT, Christiane , GRELL, Matthias , SIRRENBERG, Christian , ZENKE, Frank
发明人: FINSINGER, Dirk , BUCHSTALLER, Hans-Peter , BURGDORF, Lars , AMENDT, Christiane , GRELL, Matthias , SIRRENBERG, Christian , ZENKE, Frank
IPC分类号: C07D213/81
CPC分类号: C07D213/81 , C04B35/632 , C07C243/38 , C07D207/327 , C07D213/54 , C07D213/66 , C07D213/68 , C07D243/38 , C07D249/18 , C07D317/68 , C07D401/12 , C07D413/12
摘要: The present invention relates to diacylhydrazine derivatives of formula I, the use of the compounds of formula I as inhibitors of raf-kinase, the use of the compounds of formula I for the manufacture of a pharmaceutical composition and a method of treatment, comprising administering said pharmaceutical composition to a patient.
摘要翻译: 本发明涉及式I的二酰肼衍生物,式I化合物作为raf-激酶抑制剂的用途,式I化合物在制备药物组合物中的用途及其治疗方法,包括给予所述 药物组合物给患者。
-
公开(公告)号:WO0179492A2
公开(公告)日:2001-10-25
申请号:PCT/EP0104296
申请日:2001-04-17
申请人: MERCK PATENT GMBH , GRELL MATTHIAS , DUECKER KLAUS
发明人: GRELL MATTHIAS , DUECKER KLAUS
IPC分类号: G01N33/50 , C07K14/47 , C07K16/18 , C07K16/46 , C07K19/00 , C12N1/15 , C12N1/19 , C12N1/21 , C12N5/10 , C12N15/09 , C12N15/12 , C12P21/02 , C12Q1/68 , G01N33/15 , G01N33/53 , G01N33/68
CPC分类号: C07K14/47 , C07K2319/30
摘要: New Lipid Binding Protein 3 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing New Lipid Binding Protein 3 polypeptides and polynucleotides in diagnostic assays.
摘要翻译: 公开了新的脂质结合蛋白3多肽和多核苷酸以及通过重组技术产生这种多肽的方法。 还公开了在诊断测定中利用新型脂质结合蛋白3多肽和多核苷酸的方法。
-
-
-
-
-
-
-
-
-